Argus News - Health Minister Reveals Shocking Counterfeit Drug Data

Bhubaneswar, Dec 2: The alarming rise of counterfeit and substandard medicines in India has come under sharp focus, with official data revealing that 168 fake medicines and 388 low-quality drugs were identified between 2021 and 2024-25.

The information was disclosed in a written reply by the Odisha Health Minister Mukesh Mahaling during the Winter Session of the State Assembly, highlighting the scale of the challenge in ensuring drug safety.

According to the report, fake medicines worth more than ₹2.5 crore were seized during this period. These counterfeit drugs were found circulating in markets, posing serious risks to public health.

Alongside, 388 medicines were classified as “Not of Standard Quality” (NSQ), meaning they failed to meet essential quality and efficacy benchmarks required for safe consumption.

Also read: ‘Sanchar Saathi’ App Mandatory on All New Phones – Know More

Year-wise data shows that in 2021, 79 fake medicines were detected, followed by 64 in 2022, 14 in 2023, and 11 in 2024. While the numbers appear to have declined in recent years, authorities caution that counterfeiters are constantly evolving their methods, making vigilance critical.

Fake versions of commonly used medicines such as Telma 40, Pan 40, O2, Zerodal SP, Raniti, Paracetamol Pediatric Syrup, Amlokind, Paracetamol Tablet, Pantaprazole, Levocetirizine, Pantap-40, Clavam 625, and Rabeprazole are also circulating in the market.

The Health Ministry emphasized that strict monitoring mechanisms are in place, including regular inspections, testing of drug samples, and coordinated raids to curb the menace. Officials also noted that awareness campaigns are being conducted to educate consumers about the dangers of purchasing medicines from unauthorized sources.

The counterfeit and substandard medicines are not only ineffective in treating illnesses but can also cause severe side effects, leading to life-threatening situations. The government’s crackdown aims to protect citizens from such risks and ensure that only safe, effective drugs reach the market.

The fight against fake medicines remains a critical priority for India’s healthcare system.